Document is current
Any future updates will be listed below
-
Authors
MacDonald, Martha
Fonseca, Pablo A. S.
Johnson, Kory R.
Murray, Erin M. https://orcid.org/0000-0003-4179-7717
Kember, Rachel L. https://orcid.org/0000-0001-8820-2659
Kranzler, Henry R.
Mayfield, R. Dayne https://orcid.org/0000-0002-8045-1789
da Silva, Daniel https://orcid.org/0000-0003-0033-3270
- License Information
-
More Information
Article History
Received: 30 April 2024
Revised: 23 September 2024
Accepted: 27 September 2024
First Online: 14 October 2024
Competing interests
: Kranzler is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics; and a holder of U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonizts,” issued 26 January 2021.
: This was a secondary analysis, utilizing data previously published, with ethical approval obtained for each of the original studies.
